Two poster presentations include preclinical data ... Ventures and was formed following decades of work on ciliopathies at University College London by co-founders Professor Phil Beales and ...

The poster presentations will include preclinical safety and efficacy results, highlighting STRO-004's significant anti-tumor activity and safety profile. Sutro's CEO, Jane Chung, expressed ...

Morial Convention Center in New Orleans, LA. Two poster presentations include preclinical data that support the dosing regiment and study protocol for the subretinal clinical study for its lead ...

Title: Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an ...

SAN DIEGO, April 29, 2025 /PRNewswire/ -- NEUVOGEN, Inc. ("NEUVOGEN THERAPEUTICS" or "NEUVOGEN"), a San Diego based biotechnology company, will present data that its next generation whole tumor ...

SAN DIEGO, April 29, 2025 /PRNewswire/ -- NEUVOGEN, Inc. ("NEUVOGEN THERAPEUTICS" or "NEUVOGEN"), a San Diego based biotechnology company, will present data that its next generation whole tumor cell ...

Latus Bio Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced upcoming oral and poster presentations at the American Society for Gene and Cell Therapy ...

The Undergraduate Research Symposium was held on Thursday at the Illini Union displaying research by students from all disciplines.

today announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4-8, 2025, in Salt Lake City, Utah.

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt Disease type 1 (STGD1) and ...

today announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4–8, 2025, in Salt Lake City ...

including two oral presentations, at the upcoming 28 th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) that will take place May 13-17, 2025, in New Orleans, Louisiana. "We ...